Adlai Nortye Group Ltd. (ANL) Form 6-K — Oct 15, 2026

Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate its lead asset AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC targeting CEACAM5, in combination with cetuximab. The partnership supports Adlai Nortye's ongoing global Phase I trial in CEACAM5-enriched RAS-addicted solid tumors, with Lilly supplying cetuximab at no cost for U.S. sites and Merck KGaA supplying it at no cost for Australia and China sites.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.